A haemophilia A and B molecular genetic diagnostic programme in Hungary: a highly informative and cost-effective strategy

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 7; no. 3; pp. 306 - 312
• Main Authors: Klein, I., Andrikovics, H., Bors, A., Nemes, L., Tordai, A., Váradi, A.
• Format: Journal Article
• Language: English
• Published: Oxford UK Blackwell Science Ltd 01.05.2001
• Subjects: carrier diagnosis; Chromosome Inversion; Cost-Benefit Analysis; DNA Mutational Analysis; DNA polymorphism; Family Health; Female; gene inversion; Genetic Carrier Screening; Genetic Testing - economics; Genetic Testing - methods; Genetic Testing - organization & administration; haemophilia A; haemophilia B; Hemophilia A - diagnosis; Hemophilia A - economics; Hemophilia A - genetics; Hemophilia B - diagnosis; Hemophilia B - economics; Hemophilia B - genetics; Humans; Hungary - epidemiology; Male; Pedigree; Polymorphism, Genetic; prenatal diagnosis; Prenatal Diagnosis - economics
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1046/j.1365-2516.2001.00497.x

Our aim was to set up a protocol in order to provide carrier and prenatal diagnosis to Hungarian haemophilia A (HA) and B (HB) patients and their relatives. For HA, a combination of direct mutation detection and some indirect marker analyses were used: the detection of the inversion mutation and analysis of three polymorphisms, BclI, IVS13 (CA)n and P39(CA)n. In severe cases, direct mutation detection was performed first. In inversion‐negative severe cases and in moderate and mild cases, indirect methods were used. For carrier and prenatal diagnosis in HB, four polymorphisms, DdeI, TaqI, XmnI, and HhaI were examined. Our DNA bank contains samples from 50 HA families (34 severe, 15 moderate and one mild) and seven HB families from different parts of the country. In 100% of the HA cases either the gene inversion and/or at least one of the polymorphisms was found to be informative for carrier or prenatal diagnosis. In the HB cases, an informative marker was found in 95% of the cases (19 of 20). We conclude that these strategies are sufficient to make genetic diagnosis available to almost all HA and HB families in the region. This approach is highly informative and cost‐effective, so it can be very useful in countries where direct sequencing of genes for factor VIII and IX is not available for routine diagnosis.